AptuCure Bio Israeli Company

AptuCure Bio is developing AptuBodies, unique revolutionary synthetic aptamer-based nanoparticles mimicking antibody activity, that can be directed virtually against any target. An AptuBody binds non-covalently to the Fab fragment of circulating IgG antibody and thus provides the antibody a new antigen binding domain, targeted to a designed cell surface markers. An AptuBody will complex with any IgG, directing the complex to its target and activating safe natural complement-mediated immune response. The AptuBodies/IgG complex mimics therapeutic antibodies, by binding to cell surface antigens and promote activation of the natural immune system which aimed to kill the target cells, such as the complement system and killer cells. AptuBodies can replace humanized antibodies, for the treatment of cancer, infectious disease, and auto-immune disease.